anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a new low-toxicity agent for conquering anti-cancer agent resistance or an agent for enhancing an anti-cancer effect. CONSTITUTION: This agent for conquering anti-cancer agent resistance comprises a 1,4-dihydropyridine compound of the formula [R1 is a COO-A-(3-pyridyl); A is a 3-6C alkylene; R2 is a 2-10C alkyl, alkenyl, alkynyl, a substituent group- containing lower alkyl, etc.; R3 is as shown for R1 or a COO-R4 ; R4 is a lower alkyl] as an active ingredient. The compound of the formula has extremely increasing actin on sensitivity of cancerous cells to an anti-cancer agent, especially on sensitivity of cancerous cells having acquired resistance to an anti-cancer agent to an anti-cancer agent, prolongs a survival time of a tumor bearing animal and has almost no calcium path blocking action.  A dose is 5-1,000mg/day/adult in the case of oral administration and 1-500mg/day/adult in the case of parenteral administration. 2,6-Dimethyl-4-isopropyl-1,4-dihydrophyridine-3,5- dicarboxylic acid-bis[3-(3-pyridyl)propyl] ester may be cited as the compound of the formula.
Lung cancer incidence is substantially elevated among people infected with human immunodeficiency virus (HIV). Although frequent smoking may partly explain this increase, recent work suggests other factors may also be involved. To better characterize smoking habits and lung cancer risk in HIV-infected people, the investigators propose a cross-sectional pilot study of HIV-infected and uninfected injection drug users in the ALIVE cohort in Baltimore, Maryland. A detailed questionnaire on smoking behaviors and other lung cancer risk factors will be administered to all \~ 1600 cohort subjects. In addition, the investigators will measure serum cotinine (a marker of recent smoking intensity) for a sample of 340 African American males from the cohort, stratified on the amount of cigarette use, HIV status, and CD4 count. Spirometry will be performed on the entire group of 1600 subjects, to assess for chronic obstructive pulmonary disease. Differences between HIV-infected and uninfected subjects in smoking habits, exposure to tobacco, or lung damage will identify areas for future investigation.
A method, a processing device, and a computer program product are provided. At least one processing device correlates textual medical information related to the subject with characteristics of an image of a medical condition of the subject to generate a subject signature. The at least one processing device compares the subject signature with multiple reference signatures to determine at least one reference signature corresponding to the subject signature. Each reference signature is associated with a corresponding medical condition and is generated by correlating textual medical information regarding the corresponding medical condition with characteristics of an image of the corresponding medical condition. The at least one processing device identifies the medical condition of the subject based on the medical conditions associated with the determined at least one reference signature. Information is provided regarding the identified medical condition of the subject.
Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
The present invention relates to the predicting a response to immune checkpoint inhibitors (ICI). In this study, the inventors addressed the issue of response to ICIs based on two independent prospective cohorts of 44 and 73 patients with dMMR/MSI mCRC, respectively the multicentric NIPICOL clinical trial and the prospective ImmunoMSI cohort. Following central reassessment for dMMR/MSI status using gold standard methods to discard misdiagnosed mCRC cases, combined DNA and RNA sequencing of the tumor tissues from these patients was performed. Following supervised analysis of the molecular profiles data which failed to confirm previously proposed DNA/RNA indicators for response to treatment, the use of innovative methods allowed them to identify robust independent DNA and RNA signatures for predicting resistance to ICI. Testing of several retrospective and prospective cohorts regrouping 446 patients with metastatic or nonmetastatic MSI CRC untreated with ICI was also performed to evaluate the specificity of the predictive nature of these indicators, i.e., in the context of immune checkpoint blockade therapy. Thus, the present invention relates to a method of predicting a response to immune checkpoint inhibitors (ICI) in a patient with an MSI cancer comprising determining the microsatellite (MS) variation status of a set of selected genes and using a machine learning algorithm.
Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-η. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, useful for practicing the methods, and mammalian cells containing the HSV-derived vectors.
Participants will receive 45 mcg CssBA with 0.5 mcg dmLT vaccine intramuscular injection on Days 1, 22 and 43, outpatient. Participants who meet challenge criteria will orally receive 1x10\^10 cfu of ETEC strain B7A, inpatient, approximately 28 days after the third dose of study agent. N= 18.
1450536 Sustained release tablets containing lithium carbonate DELANDALE LABORATORIES Ltd 20 Nov 1973 54671/72 Addition to 1209093 Heading A5B Sustained release pharmaceutical tablets for the treatment of manic depressive states, comprising powdered lithium carbonate; a sustained release agent comprising a mixture of glyceryl mono-, di- and tri-esters of one or mere C 16-18  straight chain saturated fatty acids and one or more excipients, are prepared by coating a mixture of powdered lithium carbonate and one or more excipients with the sustained release agent, granulating the mixture using about (11.55 to 24.5 p) litres of water per 100 kg lithium carbonate where p is the bulk density of the lithium carbonate in grams per c.c., screening to form a granulate whose particles are all less than 12 BS Mesh, from 20 to 30% of which have particle sizes in the range of from 12 BS to 60 BS Mesh and from 70 to 80% of which have a particle size below 60 BS Mesh, and compressing the granulate into tablets. The tablets may comprise a filler e.g. mannitol, a binding agent e.g. gum acacia and a lubricant e.g. magnesium stearate. The tablets preferably contain 9.5 to 11.4 parts by weight of the mixture of glyceryl esters per 100 parts by weight of lithium carbonate. Preferably the sustained release agent is added in alcohol solution and at 68C or higher, the powdered lithium carbonate and filler being pre-heated to about this temperature before adding the solution.
Transforming growth factor-β (TGFβ) drives fibrosis and disease progression in a number of chronic disorders, but targeting this ubiquitously expressed cytokine may not yield a viable and safe antifibrotic therapy. Here, we sought to identify alternative ways to inhibit TGFβ signaling using human hepatic stellate cells and macrophages from humans and mice in vitro, as well as mouse models of liver, kidney, and lung fibrosis. We identified Mer tyrosine kinase (MERTK) as a TGFβ-inducible effector of fibrosis that was up-regulated during fibrosis in multiple organs in three mouse models. We confirmed these findings in liver biopsy samples from patients with metabolic dysfunction-associated fatty liver disease (MAFLD). MERTK also induced TGFβ expression and drove TGFβ signaling resulting in a positive feedback loop that promoted fibrosis in cultured cells. MERTK regulated both canonical and noncanonical TGFβ signaling in both mouse and human cells in vitro. MERTK increased transcription of genes regulating fibrosis by modulating chromatin accessibility and RNA polymerase II activity. In each of the three mouse models, disrupting the fibrosis-promoting signaling loop by reducing MERTK expression reduced organ fibrosis. Pharmacological inhibition of MERTK reduced fibrosis in these mouse models either when initiated immediately after injury or when initiated after fibrosis was established. Together, these data suggest that MERTK plays a role in modulating organ fibrosis and may be a potential target for treating fibrotic diseases.
BACKGROUND: Wernicke's encephalopathy (WE) is an acute neurological syndrome resulting from thiamine (vitamin B1) deficiency. It has been recognized increasingly in non-alcoholic patients, such as in the condition of malnutrition. Recent literature has shed light on uncommon symptoms and neuroimaging findings.
CASE REPORT: We reported a case of a 44-year-old male who initially presented with bilateral hearing loss, and exhibited abnormality in the splenium of the corpus callosum on magnetic resonance imaging (MRI) diffusion-weighted imaging sequence. On the following day the patient developed new symptoms, including unstable walking, double vision and hallucination. The subsequent brain MRI demonstrated lesions involving periaqueductal grey matter and bilateral medial thalamus, indicating the diagnosis of WE. Empirical treatment with intravenous thiamine resulted in complete clinical and radiological resolution.
CONCLUSION: To the best of our knowledge, the current case is the first report of WE in literature with uncommon but reversible manifestations. This case warns us to maintain a heightened level of suspicion for WE in malnourished patients with neurological deficits, despite the possibility of atypical presentations encompassing bilateral hearing disturbances and unusual neuroradiological results. Early diagnosis and timely administration of thiamine in WE are likely to lead to a favorable outcome and full recovery.
Cardiovascular disease (CVD) is the leading cause of death in the world and many comorbid conditions (i.e. diabetes, obesity) can affect overall CVD risk. There is increasing interest into the role that skeletal muscle health plays in mediating CVD risk, particularly in metabolic disease states (ie. obesity and diabetes). Whole body vibration (WBV) has emerged as an exercise mimetic that may be more tolerable than traditional modes of exercise, such as treadmill walking/running or cycling. Similar to traditional exercise modalities, WBV can elicit beneficial metabolic effects. In fact, a single bout of WBV increases circulating concentrations of IL-6, which correspond with the normalization of glucose and insulin in obese individuals. The proposed pilot investigation will provide the foundation to begin understanding the molecular and physiological mechanisms of how sub-acute WBV can improve overall CVD risk. We hypothesize that home based WBV will decrease CVD risk by improving skeletal muscle and vascular function via a decrease in systemic inflammation.
Age-related Macular Degeneration is the most cause of blindness in the industrialised countries. There are few French epidemiological data on this disease. Worldwide, studies have included a small number of very old subjects. Thus, it is important to estimate the AMD incidence in an elderly French population, in order to evaluate more precisely the number of cases in the French population. Besides, some clinical, genetic and modifiable parameters predisposing to the AMD are under study. The aim of the ECLAIR project is to study the 8-year incidence of AMD in an elderly French population and to identify the predisposing factors. It is based on an existing cohort study (ALIENOR) in which some clinical, genetic and modifiable data were collected at baseline, 2 and 4 years. It is the only cohort study performed in France in this field since fifteen years in parallel with another one performed in Dijon according to the same methodology. It is important to extend the study to 8 years in order to have a sufficient statistical power for the identification of predisposing factors. In the ECLAIR study, there is no treatment. The subjects will be followed during 2 years (6 and 8 years after baseline of the Alienor study). The visit 1 (A0) will be the inclusion visit where the subjects will sign the inform consent and will perform ophthalmological examinations. The subjects will come back 2 years later for the visit 2 (A2). In this second visit, the ophthalmological examinations will be the same that is: measure of clinical parameters, measurement of visual acuity exams, retinophotography,spectral domain optical coherence tomography (SD-OCT), intraocular pressure, retinal imaging (OPTOMAP), axial length (IOL master)
The invention provides the compositions that comprises canine influenza virus and dog respiratory and enteric coronavirus.It can further include bordetella bronchiseptica (Bordetella? bronchiseptica), pertactin (pertactin), canine parainfluenza virus (canine? parainfluenza? and hepatitis infectiosa canis virus serotype 2 type (canine virus)? adenovirus? serotype2).Said composition effectively can be treated or be prevented to comprise the dog respiratory tract disease of canine infectious respiratory disease syndrome.
Morphofunctional assessment was developed to evaluate disease-related malnutrition. However, it can also be used to assess cardiometabolic risk, as excess adiposity increases this risk. Phenylketonuria (PKU) is the most prevalent inherited metabolic disease among adults, and obesity in PKU has recently gained interest, although fat mass correlates better with cardiometabolic risk than body mass index. In this systematic review, the objective was to assess whether adult patients with PKU have higher fat mass than healthy controls. Studies of adult PKU patients undergoing dietary treatment in a metabolic clinic reporting fat mass were included. The PubMed and EMBASE databases were searched. Relevance of articles, data collection, and risk of bias were evaluated by two independent reviewers. Ten articles were evaluated, six with a control group, including 310 subjects with PKU, 62 with mild hyperphenylalaninemia, and 157 controls. One study reported a significant and four a tendency towards an increased fat mass in all patients or only females with PKU. Limitations included not having a healthy control group, not reporting sex-specific results and using different techniques to assess fat mass. Evaluation of fat mass should be included in the morphofunctional assessment of cardiometabolic risk in adult patients with PKU.
Systems and methods for generating a predicted event log are provided. A time series resulting from a test of a medical machine is received. The time series is encoded using an encoder of a transformer network. A predicted event log for the medical machine is generated based on the encoded time series using a decoder of the transformer network. The predicted event log comprises predicted events and associated action plan recommendations. The predicted event log is output.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor highly inhibiting tyrosinase activity involved in melanogenesis and usable in e.g. bleaching cosmetics, by including one or more kinds of specific flavonoids as active ingredient. SOLUTION: This tyrosinase activity inhibitor is obtained by including (A) as active ingredient, >=0.0001 wt.% of one or more kinds of flavonoids of formula I to formula V (R is OH, carbonyl, a 1-9C alkyl, alkenyl- or alkoxy; (n) is 0-3) or the like and (B) as necessary, another tyrosinase activity inhibitor. To prepare the component A, flavonoids or isoflavonoids afforded by e.g. extraction from natural plants are nitrated and then aminated by conventional means fallowed by addition of hydroxyl groups. The other objective cosmetic is obtained by including >=0.0001 wt.%, pref. 0.0001-20 wt.%, more pref. 0.0001-10 wt.% of the flavonoids.
OBJECTIVES: Iatrogenic cutaneous siderosis is a well-recognized dermatologic complication after parenteral iron infusion. The condition manifests as discrete, hyperpigmented patches near the site of injection. Most cases do not resolve spontaneously, leading to significant aesthetic and psychological distress to patients. A recent case of iatrogenic cutaneous siderosis at our institution prompted a systematic review of the efficacy of energy-based devices previously reported in the treatment of this condition.
METHODS: PubMed and Cochrane databases were searched for all peer-reviewed articles published using the following search terms: "iron OR heme OR hemosiderosis OR siderosis" and "hyperpigmentation OR staining OR tattoo." Articles reporting on energy-based devices in the treatment of iron-induced hyperpigmentation were included.
RESULTS: A total of seven articles and 54 total patients were included in this review. All patients, including the patient treated at our institution, were female, with an average age of 44 years. Hyperpigmentation was most commonly associated with intravenous iron infusion (48/54, 89%), on the arm or forearm (44/54, 81%), and used for the treatment of underlying iron deficiency anemia (54/54, 100%). The application of six different nanosecond or picosecond quality-switched laser systems was reported in the treatment of cutaneous siderosis, with wavelengths ranging from 532 to 1064 nm. Spot sizes varied between 2 and 7 mm, with energy fluences spanning 0.5-40 J/cm2 depending on both the device and spot size. Outcomes were measured after an average of 5.4 laser treatments and 10.4 months, with over half of all reported patients experiencing complete clearance (27/50, 54%). Our patient received treatment in three test areas with picosecond alexandrite 785 nm, nanosecond Nd:YAG 532 nm, and picosecond Nd:YAG 532 nm devices. The nanosecond Nd:YAG 532 nm treated area demonstrated the greatest improvement, and the entire arm was subsequently treated with this device.
CONCLUSIONS: Despite the often intractable nature of iatrogenic cutaneous siderosis, laser surgery is a reasonable and safe treatment modality for patients seeking cosmetic improvement of this dyschromia. Dermatologists should be aware of this entity and the efficacy of the energy-based devices currently in our armamentarium. A combination approach may need to be utilized with different wavelengths and pulsed widths to target iron pigment in both dermal and subcutaneous layers.
If the subjects qualify to take part in this research study, they will undergo the following procedures.

Subjects will be asked to abstain from alcoholic beverages (24 hours), grapefruit products, herbal supplements/teas, and over-the-counter medications (48 hours) prior to the study visits. There will be two study periods in this study. During each period all the subjects are outpatients and there will be no overnight stay. During each study period, the subjects will come to the University of Florida Clinical Research Center (UF CRC) three times: on Day -1, Day 1, and Day 2, respectively. Subjects will report to the UF CRC the day before Day 1 (i.e. Day -1) to have clinical lab test and urine pregnancy test (female only). Subjects will come to UF CRC at 6:30 a.m. on Day 1 and Day 2 of each study visit. During the morning of each study period (around 8:30 am) subjects will be randomly assigned to receive a single oral dose of dasatinib 20 mg either with or without a single oral dose of imatinib 400 mg administered one hour prior to dasatinib. After the first study visit, the subjects will return one to two weeks later for the second study visit, receiving the opposite treatment. The treatment order for the study visits will be assigned randomly. The end point measures for this study are plasma concentrations of dasatinib. A total of twelve (12) blood samples will be collected for a total amount of 84 ml (about 3 ounces or about 6 tablespoonsful) for each subject during each study period.
People living with HIV/AIDS (PLWHA) are known to have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. Although a primary rationale for conducting this study is reducing health disparities among PLWHA, there is a potential benefit of the proposed work from a prevention perspective given that combustible cigarette smoking is an independent risk factor for non-adherence to ART and may decrease the effectiveness of HAART. Smoking-related illnesses are leading causes of non-HIV/AIDS-related deaths among People Living with HIV/AIDS (PLWHA). Electronic cigarettes (E-cigarettes) could help people reduce the harm of combustible cigarette (CC) through reductions in number of Cigarettes per Day (CPD) or quitting CC completely by addressing both nicotine and behavioral dependence. Unlike CC, EC are not associated with coronary heart disease or myocardial infarction. The purpose is to identify barriers and facilitators, as well as assess preliminary effectiveness of e-cigarettes as a harm reduction strategy among PLWHA.
Acetylated cardiotonic glucosides are produced by reacting the glucoside with an alkyl orthoacetate and submitting the resulting cyclic orthoacetate to partial saponification. The intermediate cyclic orthoacetate may be isolated and/or other free OH gps. acetylated if desired. This process enables acetyl gps. to be introduced into desired positions on the pyrannoside radical of the glocoside. Preferred products are alpha-digoxin, alpha-digitoxin, and 2'-acetyl-proscillaridin. The products are of value in the treatment of cardiac insufficiency. They are more readily absorbed than the parent glucosides.
The invention provides a preparation method of a triple-responsiveness polymer porous microsphere. Cheap polystyrene is used as a raw material, nano hydroxyapatite is used as a nucleating agent, and the polystyrene is nucleated and crystallized by a thermally induced phase separation method to obtain the magnetic porous microsphere. The activated magnetic porous microspheres are grafted with N-isopropyl acrylamide and acrylic acid on polystyrene magnetic porous microspheres by an ultraviolet radiation polymerization method. The temperature sensitivity of N-isopropyl acrylamide, the pH responsiveness of acrylic acid and the magnetism of ferroferric oxide are utilized to ensure that the prepared porous microspheres have triple responsiveness of temperature, pH and magnetism. The large specific surface area and the high porosity of the polystyrene porous microspheres are utilized, so that the magnetic porous microspheres are beneficial to the diffusion of water molecules during swelling and shrinkage, and the temperature and the pH response rate of the porous microspheres are greatly improved. The aim of targeted therapy is achieved by utilizing the magnetic guidance of the ferroferric oxide magnetic nanoparticles. The method has the advantages of simple process, high yield, and suitability for industrial production.